T cell receptor gamma joining 2Genealiases: J2 · TCRGJ2
Q-omics provides the consensus-scored TRGJ2 profile across patient tissues and cancer cell-line models. TRGJ2 expression is associated with patient survival in 4 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, TRGJ2 is differentially expressed in 3, with the highest sampling consensus in PRAD. Additionally, TRGJ2 RNA expression shows 7,141 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, PRAD, and LSCC as cancer lineages where TRGJ2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRGJ2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRGJ2 survival associations across molecular data types. TRGJ2 RNA expression shows survival associations in the most cancer types (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRGJ2 RNA expression–survival associations across cancer types. High TRGJ2 expression shows unfavorable associations in BLCA, THCA and COAD, but favorable associations in KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for TRGJ2 RNA expression.
This table summarizes TRGJ2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for TRGJ2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRGJ2 shows higher tumor expression in PRAD, ESCA and KIRC. The PRAD box plot shows higher TRGJ2 RNA expression in tumor versus normal tissue (log2 FC = +0.636, t-test p < 0.001).
This table shows molecular features associated with TRGJ2 in patient tissues and cancer cell lines. In patient samples, TRGJ2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
